Treprostinil (extended-release tablet)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Treprostinil (extended-release tablet) is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
There is limited information regarding Treprostinil (extended-release tablet) FDA-Labeled Indications and Dosage (Adult) in the drug label.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Treprostinil (extended-release tablet) in adult patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Treprostinil (extended-release tablet) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding Treprostinil (extended-release tablet) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Treprostinil (extended-release tablet) in pediatric patients.
Non–Guideline-Supported Use
There is limited information regarding Off-Label Non–Guideline-Supported Use of Treprostinil (extended-release tablet) in pediatric patients.
Contraindications
There is limited information regarding Treprostinil (extended-release tablet) Contraindications in the drug label.
Warnings
There is limited information regarding Treprostinil (extended-release tablet) Warnings' in the drug label.
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Treprostinil (extended-release tablet) Clinical Trials Experience in the drug label.
Postmarketing Experience
There is limited information regarding Treprostinil (extended-release tablet) Postmarketing Experience in the drug label.
Drug Interactions
There is limited information regarding Treprostinil (extended-release tablet) Drug Interactions in the drug label.
Use in Specific Populations
Pregnancy
Pregnancy Category (FDA):
There is no FDA guidance on usage of Treprostinil (extended-release tablet) in women who are pregnant.
Pregnancy Category (AUS):
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Treprostinil (extended-release tablet) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Treprostinil (extended-release tablet) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Treprostinil (extended-release tablet) in women who are nursing.
Pediatric Use
There is no FDA guidance on the use of Treprostinil (extended-release tablet) in pediatric settings.
Geriatic Use
There is no FDA guidance on the use of Treprostinil (extended-release tablet) in geriatric settings.
Gender
There is no FDA guidance on the use of Treprostinil (extended-release tablet) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Treprostinil (extended-release tablet) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Treprostinil (extended-release tablet) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Treprostinil (extended-release tablet) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Treprostinil (extended-release tablet) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Treprostinil (extended-release tablet) in patients who are immunocompromised.
Administration and Monitoring
Administration
There is limited information regarding Treprostinil (extended-release tablet) Administration in the drug label.
Monitoring
There is limited information regarding Treprostinil (extended-release tablet) Monitoring in the drug label.
IV Compatibility
There is limited information regarding the compatibility of Treprostinil (extended-release tablet) and IV administrations.
Overdosage
There is limited information regarding Treprostinil (extended-release tablet) overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.
Pharmacology
There is limited information regarding Treprostinil (extended-release tablet) Pharmacology in the drug label.
Mechanism of Action
There is limited information regarding Treprostinil (extended-release tablet) Mechanism of Action in the drug label.
Structure
There is limited information regarding Treprostinil (extended-release tablet) Structure in the drug label.
Pharmacodynamics
There is limited information regarding Treprostinil (extended-release tablet) Pharmacodynamics in the drug label.
Pharmacokinetics
There is limited information regarding Treprostinil (extended-release tablet) Pharmacokinetics in the drug label.
Nonclinical Toxicology
There is limited information regarding Treprostinil (extended-release tablet) Nonclinical Toxicology in the drug label.
Clinical Studies
There is limited information regarding Treprostinil (extended-release tablet) Clinical Studies in the drug label.
How Supplied
There is limited information regarding Treprostinil (extended-release tablet) How Supplied in the drug label.
Storage
There is limited information regarding Treprostinil (extended-release tablet) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Treprostinil (extended-release tablet) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Treprostinil (extended-release tablet) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Treprostinil (extended-release tablet) Patient Counseling Information in the drug label.
Precautions with Alcohol
Alcohol-Treprostinil (extended-release tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
There is limited information regarding Treprostinil (extended-release tablet) Brand Names in the drug label.
Look-Alike Drug Names
There is limited information regarding Treprostinil (extended-release tablet) Look-Alike Drug Names in the drug label.
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.